Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research |
RFA-CA-23-002 (R61 Clinical Trial Not Allowed) |
R61 |
Clinical Trial Not Allowed |
09/02/2023 |
Guillermo Marquez, Ph.D. |
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research |
RFA-CA-23-007 (U01 Clinical Trial Optional) |
U01 |
Clinical Trial Optional |
09/02/2023 |
Guillermo Marquez, Ph.D. |
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research |
RFA-CA-23-010 (P50 Clinical Trial Optional) |
P50 |
Clinical Trial Optional |
09/02/2023 |
Guillermo Marquez, Ph.D. |
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research |
RFA-CA-23-003 (R33 Clinical Trial Not Allowed) |
R33 |
Clinical Trial Not Allowed |
09/02/2023 |
Guillermo Marquez, Ph.D. |
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research |
RFA-CA-23-008 (U54 Clinical Trials Optional) |
U54 |
|
09/02/2023 |
Guillermo Marquez, Ph.D. |
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) |
RFA-CA-23-011 |
|
Clinical Trial Optional |
09/02/2023 |
Guillermo Marquez, Ph.D. |
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research |
RFA-CA-23-006 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
09/02/2023 |
Guillermo Marquez, Ph.D. |
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research |
RFA-CA-23-009 (P01 Clinical Trial Optional) |
P01 |
Clinical Trial Optional |
09/02/2023 |
Guillermo Marquez, Ph.D. |
Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-20-313 (UH2/UH3 Clinical Trial Not Allowed) |
UH2, UH3 |
Clinical Trial Not Allowed |
10/11/2023 |
Lynn Sorbara, Ph.D. |
Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-20-314 (UH3 Clinical Trials Not Allowed) |
UH3 |
|
10/11/2023 |
Lynn Sorbara, Ph.D. |